News
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that preclinical research exploring key mechanisms underlying amyotrophic lateral sclerosis (ALS) pathology will be presented at the 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback